GlaxoSmithKline and Anacor Pharmaceuticals have amended and expanded their R&D pact to provide GSK the option to extend its rights around the bacterial enzyme target leucyl-tRNA synthetase (LeuRS), as well as to add new programs for tuberculosis (TB) and malaria using Anacor’s boron chemistry platform. As a result of the amendment, Anacor will receive a $5 million upfront payment as well as additional potential milestones and research funding of as much as $11.3 million by the end of 2012. A...